Hydroxyurea for the treatment of sickle cell anemia.

An 18-year-old woman with sickle cell anemia presents with recurrent painful crises, and treatment with hydroxyurea is recommended. Hydroxyurea causes a shift toward the production of red cells containing fetal hemoglobin. A possible increase in the risk of acute leukemia due to hydroxyurea therapy remains the subject of debate.

[1]  R. Ware,et al.  Hydroxyurea as an Alternative to Blood Transfusions for the Prevention of Recurrent Stroke in Children With Sickle Cell Disease , 1999 .

[2]  O. Castro,et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.

[3]  M. Gladwin,et al.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. , 2003, The Journal of clinical investigation.

[4]  Mark T Gladwin,et al.  Hemoglobin and the paracrine and endocrine functions of nitric oxide. , 2003, The New England journal of medicine.

[5]  C. Pegelow,et al.  Hydroxyurea and sickle cell anemia: effect on quality of life , 2006, Health and quality of life outcomes.

[6]  M L Terrin,et al.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.

[7]  F. Lorey,et al.  Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state , 1996, Genetic epidemiology.

[8]  O. Platt,et al.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. , 1999, Blood.

[9]  Clinton H Joiner,et al.  The effect of fetal hemoglobin on the survival characteristics of sickle cells. , 2006, Blood.

[10]  J. Scott,et al.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. , 2005, Blood.

[11]  M. Goldberg,et al.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.

[12]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[13]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[14]  K. Neldner,et al.  Hydroxyurea therapy. , 1991, Journal of the American Academy of Dermatology.

[15]  C. Steiner,et al.  Sickle Cell Disease Patients in U.S. Hospitals, 2004 , 2006 .

[16]  J. Yarbro.  Mechanism of action of hydroxyurea. , 1992, Seminars in oncology.

[17]  E. Vichinsky,et al.  Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. , 2002, The Journal of pediatrics.

[18]  T. Barbui,et al.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .

[19]  K. McIntyre,et al.  Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. , 1984, The New England journal of medicine.

[20]  K. Ataga,et al.  The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease , 2005, Journal of clinical pharmacology.

[21]  A. Shad,et al.  NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[22]  C Argote-Olivera,et al.  [Sickle-cell anemia]. , 1977, La Prensa medica mexicana.

[23]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[24]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[25]  R. Ware,et al.  Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. , 2007, Blood.

[26]  T. Konrad,et al.  Hydroxyurea therapy for sickle cell disease in community‐based practices: A survey of Florida and North Carolina hematologists/oncologists , 2005, American journal of hematology.

[27]  L A Farrer,et al.  Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea , 2007, The Pharmacogenomics Journal.

[28]  E. Vichinsky,et al.  Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. , 2000, Journal of pediatric hematology/oncology.

[29]  G. Stamatoyannopoulos.  Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.

[30]  R. Ware,et al.  Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. , 2004, The Journal of pediatrics.

[31]  Richard D Moore,et al.  Cost‐effectiveness of hydroxyurea in sickle cell anemia , 2000, American journal of hematology.

[32]  C. Haywood,et al.  Hospitalization rates and costs of care of patients with sickle‐cell anemia in the state of Maryland in the era of hydroxyurea , 2006, American journal of hematology.

[33]  F. Barton,et al.  Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea , 1999, British journal of haematology.

[34]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[35]  F. Roudot-thoraval,et al.  Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. , 2006, Haematologica.